The International Journal of Neuropsychopharmacology
July 5, 2021
Sven Melker Hagsäter, Robert Pettersson, Christopher Pettersson et al.
29 citations
Abstract Background Though drugs binding to serotonergic 5-HT2A receptors have long been claimed to influence human anxiety, it remains unclear if this receptor subtype is best described as anxiety promoting or anxiety dampening. Whereas conditioned fear expressed as freezing in rats is modified by application of 5-HT2A–acting drugs locally into different brain regions, reports on the effect of...
Educational Media Reviews Online
June 22, 2021
C. Healy
Distributed by Collective Eye Films, 1315 SE 20th Ave. #3, Portland OR 97214; 971-236-2056Produced by Tyler Chandler and Nichaols MeyersDirected by Tyler Chandler2019, Streaming, 84 mins Dosed is a Canadian documentary about a heroin addict named Adrianne. The film follows her through her long-term addictive behaviors, her family background and her attempts to break away from her addiction...
Perspectiva geográfica
June 18, 2021
Diego Hannon Ovies
1 citation
Despite the fundamental role played by psilocybin mushrooms in traditional indigenous medicine in Mexico since time immemorial, their institutional neglect and their illegal status make it impossible to deploy conservation, research and exploitation schemes for this endogenous biocultural resource. Starting from the conceptual paradigm of bioculturality and from the socio-territorial approach...
F1000Research
June 15, 2021
Kevin Mckernan, Liam T. Kane, Seth Crawford et al.
10 citations
We describe the use of high-fidelity single molecule sequencing to assemble the genome of the psychoactive Psilocybe cubensis mushroom. The genome is 46.6Mb, 46% GC, and in 32 contigs with an N50 of 3.3Mb. The BUSCO completeness scores are 97.6% with 1.2% duplicates. The Psilocybin synthesis cluster exists in a single 3.2Mb contig. The dataset is available from NCBI BioProject with accessions...
Experimental and Clinical Psychopharmacology
June 7, 2021
Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al.
53 citations
Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...
The American Journal of Drug and Alcohol Abuse
June 5, 2021
David J. Cox, Albert Garcia‐romeu, Matthew W. Johnson
29 citations
Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patterns of tobacco, opioid, and alcohol consumption. But, the specific characteristics of psychedelic experiences that lead to changes in drug consumption are unknown.Objective: Determine whether quantitative descriptions of psychedelic experiences...
Technoetic Arts
June 1, 2021
Lucas Pawlik
Data analysis from diverse medical fields suggests that we have reached a tipping point in the digitalization dynamic through the ongoing COVID-19 crisis, leading to an escalation of physical inactivity and related diseases. The lack of prioritization of physical activity designed to intervene against obesity, diabetes, loneliness, depression, anxiety disorders and suicide risk could...
Neurobiology of Learning and Memory
May 25, 2021
Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber
49 citations
The high symptomatic and biological heterogeneity of major depressive disorder (MDD) makes it very difficult to find broadly efficacious treatments that work against all symptoms. Concentrating on single core symptoms that are biologically well understood might consist of a more viable approach. The Research Domain Criteria (RDoC) framework is a trans-diagnostic dimensional approach that...
World Psychiatry
May 18, 2021
Wayne Hall
17 citations
A psychedelic drug is one that “produces thought, mood and perceptual changes otherwise rarely experienced except in dreams, contemplative and religious exaltation, flashes of vivid involuntary memory, and acute psychosis”1. It does so “without causing physical addiction, craving, major physiological disturbances, delirium, disorientation or amnesia”1. The “classic psychedelics” include...
May 12, 2021
Ioana A. Cristea, Florian Naudet, Clara Miguel
1 citation
preprint
Letter to the editor in reference to Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine 2021;384:1402-11.